Media coverage about Myovant Sciences (NYSE:MYOV) has trended somewhat positive recently, according to Accern. The research group identifies positive and negative press coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Myovant Sciences earned a coverage optimism score of 0.05 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 45.9250714065087 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Myovant Sciences (MYOV) opened at $14.25 on Friday. Myovant Sciences has a 1 year low of $9.92 and a 1 year high of $18.85. The company has a market capitalization of $858.10 and a P/E ratio of -10.11.
MYOV has been the topic of a number of analyst reports. Zacks Investment Research upgraded Myovant Sciences from a “sell” rating to a “hold” rating in a research report on Saturday, September 16th. Robert W. Baird reiterated a “buy” rating and set a $20.00 price objective on shares of Myovant Sciences in a research report on Friday, November 10th. JMP Securities reiterated an “outperform” rating and set a $25.00 price objective (up previously from $23.00) on shares of Myovant Sciences in a research report on Wednesday, October 4th. Finally, Cowen reiterated a “buy” rating on shares of Myovant Sciences in a research report on Tuesday, November 14th. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $22.50.
ILLEGAL ACTIVITY WARNING: This story was reported by Markets Daily and is the sole property of of Markets Daily. If you are accessing this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this story can be viewed at https://www.themarketsdaily.com/2018/01/12/myovant-sciences-myov-getting-somewhat-positive-press-coverage-study-finds.html.
Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for women’s health diseases and other endocrine-related disorders. Its main product candidate is Relugolix. Relugolix is an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and inhibits receptors in the anterior pituitary gland.
Receive News & Ratings for Myovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.